ライフサイエンスコーパス: Citrobacter rodentium

1 e against an epithelium-associated pathogen (Citrobacter rodentium).

2 e differentiating in response to a pathogen (Citrobacter rodentium).

3 CD4(+)CD45RB(hi) T cells, or infection with Citrobacter rodentium.

4 specially in the colon during infection with Citrobacter rodentium.

5 Salmonella enterica serovar Typhimurium and Citrobacter rodentium.

6 improves host tolerance of the mild pathogen Citrobacter rodentium.

7 evere colitis and death after infection with Citrobacter rodentium.

8 PEC and EHEC) and the natural mouse pathogen Citrobacter rodentium.

9 istration of dextran sulfate sodium (DSS) or Citrobacter rodentium.

10 ppled responses to intestinal infection with Citrobacter rodentium.

11 nce of the attaching/effacing mouse pathogen Citrobacter rodentium.

12 ir selective depletion during infection with Citrobacter rodentium.

13 itical for the clearance of the A/E pathogen Citrobacter rodentium.

14 ty against an intestinal bacterial pathogen, Citrobacter rodentium.

15 unity to the attaching-and-effacing pathogen Citrobacter rodentium.

16 zene sulfonic-acid (TNBS); or infection with Citrobacter rodentium.

17 ease induced by the model bacterial pathogen Citrobacter rodentium.

18 h the enteric pathogens Escherichia coli and Citrobacter rodentium.

19 uced colonization levels of the gut pathogen Citrobacter rodentium.

20 and ILFs in the colon during infection with Citrobacter rodentium.

21 nged orally with the enteric murine pathogen Citrobacter rodentium.

22 hanced resistance to the intestinal pathogen Citrobacter rodentium.

23 onization of the mouse colon by the bacteria Citrobacter rodentium.

24 the gram-negative enteric bacterial pathogen Citrobacter rodentium.

25 on with the gram-negative bacterial pathogen Citrobacter rodentium.

26 ost protection against a bacterial pathogen, Citrobacter rodentium.

27 ted in the A/E-lesion-forming mouse pathogen Citrobacter rodentium.

28 enteropathogenic Escherichia coli (EPEC) and Citrobacter rodentium.

29 a of mice infected with the enteric pathogen Citrobacter rodentium.

30 riage of the lethal enteric murine pathogen, Citrobacter rodentium.

31 almonella typhimurium, Shigella flexneri and Citrobacter rodentium.

32 local and systemic bacterial infection with Citrobacter rodentium.

33 s the effectiveness of oral vaccines against Citrobacter rodentium.

34 scherichia coli and their murine equivalent, Citrobacter rodentium.

35 nths in an activated state after exposure to Citrobacter rodentium.

36 cute colitis induced by the enteric pathogen Citrobacter rodentium.

37 rial infection with the noninvasive pathogen Citrobacter rodentium.

38 ction against early-life lethal infection by Citrobacter rodentium.

39 long with the anti-swarming activity against Citrobacter rodentium.

40 tion of mice by the EPEC-like mouse pathogen Citrobacter rodentium.

41 more aggressive infectious colitis caused by Citrobacter rodentium.

42 and lethal colitis by the mucosal pathogen, Citrobacter rodentium.

43 infection with the EPEC-like mouse pathogen Citrobacter rodentium.

44 impaired gut colonization resistance against Citrobacter rodentium.

45 rves in the coordination of host defenses to Citrobacter rodentium.

46 onse to the attaching and effacing bacterium Citrobacter rodentium.

47 mpaired clearance of the intestinal pathogen Citrobacter rodentium.

48 of Runx3 in ILCs exacerbated infection with Citrobacter rodentium.

49 with LPS or infected with the enteropathogen Citrobacter rodentium.

50 ssential for the protective immunity against Citrobacter rodentium.

51 asion during infection by the enteropathogen Citrobacter rodentium(4) (Cr).

52 In mice infected with Citrobacter rodentium, a model for enteropathogenic Esch

53 at germ-free animals are unable to eradicate Citrobacter rodentium, a model for human infections with

54 reover, mice lacking TACI were able to clear Citrobacter rodentium, a model pathogen for severe human

55 acid L-tryptophan protects the host against Citrobacter rodentium, a mouse AE pathogen that is widel

56 C, we constructed an Stx-producing strain of Citrobacter rodentium, a murine AE pathogen that otherwi

57 s derived from these mice were infected with Citrobacter rodentium, a murine attaching and effacing p

58 sion by enterohemorrhagic E. coli (EHEC) and Citrobacter rodentium, a murine model for EHEC.

59 Using Citrobacter rodentium, a murine model of attaching and e

60 Citrobacter rodentium, a murine model pathogen for human

61 Citrobacter rodentium, a murine model pathogen that shar

62 C57BL/6 mice were orally gavaged with Citrobacter rodentium, a murine pathogen related to huma

63 Probiotics prevent disease induced by Citrobacter rodentium, a murine-specific enteric pathoge

64 Infection with Citrobacter rodentium, a natural mouse pathogen homologo

65 Citrobacter rodentium, a natural mouse pathogen, has rec

66 Here we used Citrobacter rodentium, a pathogen that colonizes the col

67 cute colitis induced by the enteric pathogen Citrobacter rodentium Adoptive transfer of macrophage-ri

68 killing of the extracellular enteropathogen Citrobacter rodentium after phagocytosis.

69 the murine gut microbiome to infection with Citrobacter rodentium, an attaching-and-effacing bacteri

70 e exhibited impaired intestinal clearance of Citrobacter rodentium, an enteric bacterium that models

71 The lifA/efa1 gene is also present in Citrobacter rodentium, an enteric pathogen that causes a

72 wnregulation of virulence gene expression in Citrobacter rodentium, an enteric pathogen that models h

73 fense against acute bacterial infection with Citrobacter rodentium and Clostridium difficile.

74 ching and effacing (AE) pathogens, including Citrobacter rodentium and enteropathogenic Escherichia c

75 Citrobacter rodentium and Escherichia coli O157 triggere

76 ly within the colon of BT-11-treated mice in Citrobacter rodentium and IL-10(-/-) mouse models of col

77 acterium bovis bacillus Calmette-Guerin, and Citrobacter rodentium and of tumor growth in a syngeneic

78 s, Listeria monocytogenes, Escherichia coli, Citrobacter rodentium and Pseudomonas aeruginosa.

79 context of infection with the enteropathogen Citrobacter rodentium and that its presence is central f

80 y divergent enteric pathogens, the bacterium Citrobacter rodentium and the helminth Heligmosomoides p

81 P3 activators LPS and ATP, Escherichia coli, Citrobacter rodentium and transfection of LPS, AIM2 acti

82 ike toxin-producing E. coli, E. coli RDEC-1, Citrobacter rodentium, and an EPEC espB insertion mutant

83 hesins of enteropathogenic Escherichia coli, Citrobacter rodentium, and enterohemorrhagic E. coli (EH

84 tary intervention, mice were challenged with Citrobacter rodentium, and pathological responses were a

85 s, Listeria monocytogenes, Escherichia coli, Citrobacter rodentium, and Pseudomonas aeruginosa.

86 usceptible strain of the pathogenic bacteria Citrobacter rodentium, and we propose a general approach

87 erichia coli, enterohemorrhagic E. coli, and Citrobacter rodentium are classified as attaching and ef

88 erichia coli, enterohemorrhagic E. coli, and Citrobacter rodentium are classified as attaching and ef

89 e surrogate murine infection model for EHEC, Citrobacter rodentium, are all examples of microorganism

90 ice, we employed the natural murine pathogen Citrobacter rodentium as a model of EHEC virulence to in

91 In this study, we employed Citrobacter rodentium as a physiologic model of pathogen

92 98 in IECs (hCD98 Tg mice) and infected with Citrobacter rodentium as an in vivo model.

93 m the mouse attaching and effacing pathogen, Citrobacter rodentium, as a potential drug target.

94 The attaching and effacing mouse pathogen Citrobacter rodentium associates intimately with the int

95 lonization by the enteric bacterial pathogen Citrobacter rodentium by consuming amino acids, thus sta

96 for IEC-intrinsic IL-1R are unable to clear Citrobacter rodentium (C. rodentium) but are protected f

97 nificantly increased bacterial burden during Citrobacter rodentium (C. rodentium) infection in mice.

98 e encephalomyelitis (EAE) and susceptible to Citrobacter rodentium (C. rodentium) infection.

99 d cell (ILC) and T cell-derived IL-22 during Citrobacter rodentium (C.r) infection using mice that bo

100 artonella spp., Lawsonia intracellularis and Citrobacter rodentium) can induce cellular proliferation

101 ore severe pneumonia, whereas infection with Citrobacter rodentium caused worse inflammatory colitis

102 Citrobacter rodentium causes a similar colitis in mice a

103 Citrobacter rodentium causes an attaching and effacing i

104 Citrobacter rodentium causes epithelial hyperplasia and

105 We demonstrate that after infection with Citrobacter rodentium, CD4(+) LTi cells were a dominant

106 Dextran sodium sulfate (DSS) and Citrobacter rodentium colitis (CC) was induced in adult

107 Citrobacter rodentium colonizes the mouse colon in a sim

108 e more susceptible to enteric infection with Citrobacter rodentium compared to wild-type (WT) mice ev

109 es after exposure to the intestinal pathogen Citrobacter rodentium Correspondingly, AQP3(-/-) mice sh

110 crypts at days 6 and 12 post-infection with Citrobacter rodentium (CR) and tended to decline at days

111 (EPEC), enterohemorrhagic E. coli (EHEC) and Citrobacter rodentium (CR) infections, are dependent on

112 Citrobacter rodentium (CR) promotes crypt hyperplasia an

113 sent a genetics-based platform that utilises Citrobacter rodentium (CR), an enteric mouse pathogen, t

114 idly succumb when exposed to murine pathogen Citrobacter rodentium (CR), whereas pups fostered on com

115 Utilizing the Citrobacter rodentium (CR)-induced transmissible murine

116 an infection model, using the mouse pathogen Citrobacter rodentium (CR).

117 population of the diarrhea causing bacterium Citrobacter rodentium during colonization of its natural

118 enteropathogenic Escherichia coli (EPEC) and Citrobacter rodentium during mammalian infections.

119 We previously determined that the Citrobacter rodentium effector NleB possesses an intra-b

120 Furthermore, Citrobacter rodentium encodes an analogous system that e

121 Lymphocyte inhibitory factor A (lifA) in Citrobacter rodentium encodes the large toxin lymphostat

122 was tested in vivo using the mouse pathogen Citrobacter rodentium (encoding 31 effectors).

123 infected with Gram-negative bacteria such as Citrobacter rodentium, Escherichia coli, or Pseudomonas

124 Citrobacter rodentium (formally Citrobacter freundii bio

125 a coli (EPEC)-mediated disease in humans and Citrobacter rodentium (formerly C. freundii biotype 4280

126 Citrobacter rodentium (formerly Citrobacter freundii bio

127 ontrolled spread of the pathogenic bacterium Citrobacter rodentium from infected to naive female anim

128 also required for clearance of the bacterium Citrobacter rodentium from the gastrointestinal tract.

129 In mice, susceptibility to Citrobacter rodentium has been shown to be dependent on

130 tion of pathogenic Th17 cells in response to Citrobacter rodentium; however, there is no effect on no

131 ild-type mice at constraining the numbers of Citrobacter rodentium in the colon.

132 the control of mouse colonic infection with Citrobacter rodentium in the presence of T cells.

133 onses to the attaching and effacing pathogen Citrobacter rodentium in these.

134 lock the pathogenesis of the murine pathogen Citrobacter rodentium In this work, we aimed to gain a b

135 ry response to the colitis-inducing pathogen Citrobacter rodentium in vitro by inhibiting NF-kappaB a

136 n of the TLR7 agonist R848 or infection with Citrobacter rodentium in vivo.

137 activated by the colitis-inducing bacterium Citrobacter rodentium increased NO without affecting iNO

138 romote early protection against the pathogen Citrobacter rodentium, independent of CD4(+) T cells.

139 ride (LPS) and infection with mouse pathogen Citrobacter rodentium induce translocation of the nuclea

140 We found that the enteric pathogen Citrobacter rodentium induced sequential waves of IL-22-

141 entrations of fecal acylcarnitines in murine Citrobacter rodentium-induced colitis and human inflamma

142 epithelial barrier function in vitro and on Citrobacter rodentium-induced colitis in mice.

143 with an M2 phenotype and protects mice from Citrobacter rodentium-induced colitis.

144 in IL-22-dependent colitis was confirmed in Citrobacter rodentium-induced disease.

145 ucosa-associated microbiota, and exacerbates Citrobacter rodentium-induced inflammation, effects that

146 Utilizing the Citrobacter rodentium-induced transmissible murine colon

147 Citrobacter rodentium induces transmissible murine colon

148 Citrobacter rodentium induces transmissible murine colon

149 STAT3 was also required in Citrobacter rodentium-infected BMDMs for expression of p

150 bile from specific-pathogen-free, germ-free, Citrobacter rodentium-infected or Listeria monocytogenes

151 airway inflammation and influenza A virus or Citrobacter rodentium infection along with metagenomics

152 milarly opposing phenotypes were observed in Citrobacter rodentium infection and allergic asthma.

153 22 receptor IL-22RA1 protects against lethal Citrobacter rodentium infection and chemical-induced col

154 anced and associated with protection against Citrobacter rodentium infection and exacerbation of dext

155 C3 proliferation and host protection against Citrobacter rodentium infection and metabolically affect

156 sease, whereas expansion of these cells upon Citrobacter rodentium infection exacerbated pathology.

157 lsion, caused by a deficit in ILC2s, whereas Citrobacter rodentium infection is cleared efficiently.

158 Citrobacter rodentium infection of mice induces cell-med

159 ization following microbiome disruption with Citrobacter rodentium infection or antibiotic treatment,

160 disease impact, SDR was combined with either Citrobacter rodentium infection or dextran sulfate sodiu

161 nt mice are less able to eradicate a mucosal Citrobacter rodentium infection than wild-type C57BL/6 m

162 The pathogenesis of a Citrobacter rodentium infection was evaluated in mice fe

163 ency increased morbidity and mortality after Citrobacter rodentium infection with decreased secretion

164 During intestinal Citrobacter rodentium infection, a mouse model for enter

165 provides that link for the investigation of Citrobacter rodentium infection, a mouse model for enter

166 t mice exhibited increased susceptibility to Citrobacter rodentium infection, associated with the inc

167 testinal epithelial cells after T. gondii or Citrobacter rodentium infection, but also maintained the

168 KKbeta(DeltaIEC) mice efficiently controlled Citrobacter rodentium infection, IKKalpha(DeltaIEC) mice

169 Here, we demonstrate that during Citrobacter rodentium infection, murine macrophages and

170 Using mouse model of Citrobacter rodentium infection, we investigated the rol

171 Ahr-deficient mice succumbed to Citrobacter rodentium infection, whereas ectopic express

172 Using a mouse model of Citrobacter rodentium infection, which causes colitis, w

173 impaired mouse antibacterial defense against Citrobacter rodentium infection, which was associated wi

174 nate inflammatory RelA/NF-kappaB response to Citrobacter rodentium infection, while Nfkb2(-/-) mice s

175 cells (DCs) and coexpressed with IL-23 after Citrobacter rodentium infection.

176 duced by dextran sodium sulfate treatment or Citrobacter rodentium infection.

177 ole of epithelial derived ILK in response to Citrobacter rodentium infection.

178 ed responses capable of protecting mice from Citrobacter rodentium infection.

179 -22 and IL-17A after in vitro activation and Citrobacter rodentium infection.

180 arrier function and increased mortality upon Citrobacter rodentium infection.

181 ral sites, resulting in defective control of Citrobacter rodentium infection.

182 mediated colitis but are more susceptible to Citrobacter rodentium infection.

183 the duodenum during the prandial process and Citrobacter rodentium infection.

184 production, and heightened susceptibility to Citrobacter rodentium infection.

185 tivation during both Helicobacter pylori and Citrobacter rodentium infection.

186 18 and severe colonic inflammation following Citrobacter rodentium infection.

187 cus-degrading bacteria and susceptibility to Citrobacter rodentium infection.

188 critical inducers of the innate response to Citrobacter rodentium infection.

189 infection, repeated exposure to ketamine and Citrobacter rodentium infection.

190 conferred enhanced mucosal immunity against Citrobacter rodentium infection.

191 ons that T-helper cell, type 17 responses in Citrobacter rodentium infections are driven by concomita

192 otected against Clostridioides difficile and Citrobacter rodentium infections.

193 herpes simplex virus, Toxoplasma gondii, and Citrobacter rodentium infections.

194 Infection with Citrobacter rodentium initially was controlled by ILC3,

195 Citrobacter rodentium is a natural mouse pathogen relate

196 Infection of mice with Citrobacter rodentium is a robust model to study bacteri

197 Citrobacter rodentium is an attaching and effacing mouse

198 Citrobacter rodentium is an enteric bacterial pathogen o

199 Citrobacter rodentium is an enteric pathogen which attac

200 Citrobacter rodentium is an extracellular enteric mouse-

201 Infection with the bacterium Citrobacter rodentium is known to increase epithelial ce

202 Citrobacter rodentium is known to induce IL-17(+) and IL

203 Citrobacter rodentium is the causative agent of transmis

204 Citrobacter rodentium is the causative agent of transmis

205 Citrobacter rodentium is the rodent equivalent of entero

206 Citrobacter rodentium is used as an in vivo model system

207 that enterohaemorrhagic Escherichia coli and Citrobacter rodentium, its surrogate in a mouse infectio

208 bacterial family member and murine pathogen Citrobacter rodentium, its virulence strategy likely inv

209 Following oral administration of Citrobacter rodentium, LACC1 knockout (KO) mice had more

210 after infection with the intestinal pathogen Citrobacter rodentium, leading to impaired survival.

211 resistance against a murine enteropathogen, Citrobacter rodentium, leading to the death of the anima

212 The Citrobacter rodentium model mimics the pathogenesis of i

213 nvestigated the role of these enzymes in the Citrobacter rodentium model of colitis.

214 in a CD4-specific knockout of NLRX1 within a Citrobacter rodentium model of colitis.

215 hage activation and disease phenotype in the Citrobacter rodentium model of murine infectious colitis

216 that in both the dextran sodium sulfate and Citrobacter rodentium models of colitis, significantly i

217 (EHEC), enteropathogenic E. coli (EPEC), and Citrobacter rodentium Moreover, Salmonella enterica stra

218 he involvement of Map in diarrhoea using the Citrobacter rodentium mouse model of EPEC.

219 The E. coli and Citrobacter rodentium NleB effectors, as well as the Sal

220 ing infection by the murine enteric pathogen Citrobacter rodentium of the family Enterobacteriacea.

221 the competitive fitness of E. coli LF82 and Citrobacter rodentium only during inflammation.

222 ute colitis was induced by administration of Citrobacter rodentium or dextran sulfate sodium (DSS) to

223 Here, we use mice colonized with Citrobacter rodentium or the human gamma-Proteobacteria

224 macrophages infected with Escherichia coli, Citrobacter rodentium or Vibrio cholerae.

225 with EPEC, using the mouse-specific pathogen Citrobacter rodentium Our murine infant model is similar

226 n of adult females with the enteric pathogen Citrobacter rodentium protects dams and offspring agains

227 , and the introduction of the enteropathogen Citrobacter rodentium reproducibly promotes rapid select

228 infection with Anaplasma phagocytophilum and Citrobacter rodentium respectively, were used.

229 in the context of intestinal infection with Citrobacter rodentium, resulting in preserved innate imm

230 mice with the intestinal bacterial pathogen Citrobacter rodentium results in colonic mucosal hyperpl

231 ANR homologs of Vibrio cholerae, Citrobacter rodentium, Salmonella enterica and ETEC were

232 egative bacteria including Escherichia coli, Citrobacter rodentium, Salmonella typhimurium, and Shige

233 nterohemorrhagic Escherichia coli (EHEC) and Citrobacter rodentium sense and utilize galacturonic aci

234 We also identified an lpf gene cluster in Citrobacter rodentium strain ICC168 (lpf(cr)).

235 We characterized Citrobacter rodentium strains bearing deletions in indiv

236 uction in the intestines upon infection with Citrobacter rodentium, the percentage of IgA(+)CD38(+)CD

237 m highly susceptible to the enteric pathogen Citrobacter rodentium This heightened susceptibility to

238 ies have found the murine bacterial pathogen Citrobacter rodentium to provide a robust, relevant in-v

239 Here we find that the Citrobacter rodentium type I-E CRISPR-Cas system is acti

240 Citrobacter rodentium uses a type III secretion system (

241 Citrobacter rodentium uses virulence factors similar to

242 EPEC), as well as the related mouse pathogen Citrobacter rodentium, utilize a type III secretion syst

243 Citrobacter rodentium was used as a Th17-inducing infect

244 Citrobacter rodentium was used to model human Escherichi

245 rine infection model with one such pathogen, Citrobacter rodentium, was used to elucidate the importa

246 ice with the attaching and effacing bacteria Citrobacter rodentium, we defined the mechanisms and con

247 ty transposon screen in the enteric pathogen Citrobacter rodentium, we find that the bacterium requir

248 Using a mouse A/E pathogen, Citrobacter rodentium, we show that interleukin-22 (IL-2

249 Furthermore, using the murine pathogen Citrobacter rodentium, we show that L-arabinose metaboli

250 diated inflammation and host defense against Citrobacter rodentium were not impaired in the absence o

251 d inflammation by the enteric mouse pathogen Citrobacter rodentium, which causes disease similar to t

252 d the murine attaching and effacing pathogen Citrobacter rodentium, which colonizes primarily the sur

253 nse generated to the extracellular bacterium Citrobacter rodentium, which induces a mixed Th1 and Th1

254 ArgR also augments murine disease caused by Citrobacter rodentium, which is a murine pathogen extens

255 activity against the murine enteric pathogen Citrobacter rodentium, which like the related clinically

256 testinal epithelium with the rodent pathogen Citrobacter rodentium, which models human infections wit

257 ptible than wild-type mice to infection with Citrobacter rodentium, which suggests a role for PMR in

258 dered indispensable for host defence against Citrobacter rodentium, with 100% mortality of Il22(-/-)